The Effectiveness of Tiptajo Cream for Treatment of Mild to Moderate Dermatitis

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220313002

Enrollment

304

Registered

2022-03-13

Start date

2022-05-05

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatitis Dermatitis, Eczema

Interventions

Tiptajo cream containing 10% of Tiptajo oil will be used to apply on affected area of dermatitis 2 times/day for 4 weeks.,0.1% triamcinolone cream will be used to apply on affected area of dermatitis

Experimental Drug,Active Comparator Drug

10% Tiptajo cream,0.1% triamcinolone cream

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Male or female with age from 18 to 60 years 2. Participants who diagnosed mild to moderate dermatitis 3. Participants who willing to participate the study

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding woman. 2. Participants with elevated liver enzymes more than two times of normal upper limit. 3. Participants with chronic kidney disease or acute kidney injury. 4. Participants who experienced allergy to any ingredient of Tiptajo cream or topical steroids. 5. Participants with severe dermatitis. 6. Participants with other underlying diseases or medical problems that would interfere with the study. 7. Participants who undergo other treatments for dermatitis (e.g., laser or other topical medications) 8. Participants with other skin diseases that required treatment with other medications (e.g., fungal infections, psoriasis, acne).

Design outcomes

Primary

Measure	Time frame
Eczema Area and Severity Index (EASI75) Week 4 Eczema Area and Severity Index (EASI75)	—

Secondary

Measure	Time frame
Sign and symptom of dermatitis, severity of dermatitis, safety outcomes At week 1, 2 and 4 Investigator global assessment (IGA), Visual analogue scale (VAS), Adverse events (AEs),Severity of dermatitis At week 2 Eczema Area and Severity Index (EASI75),Severity of dermatitis At week 2 and 4 Eczema Area and Severity Index scores (EASI scores),Safety outcome At week 4 levels of liver and renal function tests	—

Measure

Time frame

Sign and symptom of dermatitis, severity of dermatitis, safety outcomes At week 1, 2 and 4 Investigator global assessment (IGA), Visual analogue scale (VAS), Adverse events (AEs),Severity of dermatitis At week 2 Eczema Area and Severity Index (EASI75),Severity of dermatitis At week 2 and 4 Eczema Area and Severity Index scores (EASI scores),Safety outcome At week 4 levels of liver and renal function tests

—

Countries

Thailand

Contacts

Public ContactRatree Sawangjit

Mahasarakham University

ratree.m@msu.ac.th0911377449

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026